In 2020, Sano Genetics embarked on a three-year observational study aimed at unraveling the genetic underpinnings of long COVID, successfully identifying and genetically screening nearly 3,000 patients.

This foundational work caught the attention of a top-ten pharmaceutical company and led to a collaborative effort to further explore novel biomarkers associated with long COVID through a focused clinical study of 75 individuals experiencing prolonged post-COVID symptoms.

Sano's comprehensive strategy, combining thoughtful patient engagement and innovative screening processes, not only fulfilled but accelerated the recruitment needs, marking a significant stride in advancing long COVID research and potential therapeutic interventions.

Download the case study to learn more.